These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23412019)

  • 21. The challenge of overactive bladder therapy: alternative to antimuscarinic agents.
    Lazzeri M; Spinelli M
    Int Braz J Urol; 2006; 32(6):620-30. PubMed ID: 17201939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Position statement: a clinical approach to the management of adult non-neurogenic overactive bladder.
    Chung E; Lee D; Gani J; Gillman M; Maher C; Brennan J; Johns Putra L; Ahmad L; Chan LL
    Med J Aust; 2018 Jan; 208(1):41-45. PubMed ID: 29320672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Management of overactive bladder in women].
    Peyronnet B; Rigole H; Damphousse M; Manunta A
    Prog Urol; 2015 Nov; 25(14):877-83. PubMed ID: 26169251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neuromodulation as a treatment for overactive bladder syndrome].
    Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
    Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overactive bladder.
    Henderson E; Drake M
    Maturitas; 2010 Jul; 66(3):257-62. PubMed ID: 20399043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel uses for antidiuresis.
    Hashim H; Abrams P
    Int J Clin Pract Suppl; 2007 Sep; (155):32-6. PubMed ID: 17727577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Update on the second line management of idiopathic overactive bladder].
    Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
    Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
    Kantartzis K; Shepherd J
    Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaginal laser for overactive bladder syndrome.
    Charalampous I; Tailor VK; Digesu A
    Int Urogynecol J; 2020 Aug; 31(8):1515-1517. PubMed ID: 32399906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation and Treatment of Overactive Bladder in Women.
    Raju R; Linder BJ
    Mayo Clin Proc; 2020 Feb; 95(2):370-377. PubMed ID: 32029089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New evidence in the treatment of overactive bladder.
    Brown ET; Martin L; Dmochowski RR
    Curr Opin Obstet Gynecol; 2015 Oct; 27(5):366-72. PubMed ID: 26308197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intradetrusor injection of botulinum toxin for the management of refractory overactive bladder syndrome: an update.
    Al-Shaiji TF
    Surg Innov; 2013 Aug; 20(4):351-5. PubMed ID: 22964263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
    Liu HT; Lin H; Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leptin - a novel pharmacological agent for treatment of women with overactive bladder symptoms?
    Wuntakal R; Sharma S; Kaler M; Hollingworth T
    Med Hypotheses; 2012 Dec; 79(6):856-7. PubMed ID: 23026705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current management and future perspectives of overactive bladder (OAB) pharmacotherapy.
    Dobrek Ł; Juszczak K; Wyczółkowski M; Thor PJ
    Acta Pol Pharm; 2011; 68(6):807-21. PubMed ID: 22125944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concepts in the management of the overactive bladder in women.
    Sivalingam N; Loh KY
    Med J Malaysia; 2012 Feb; 67(1):137-41; quiz 142. PubMed ID: 22582572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.